Clinical Research & TrialsGLP-1 drugs have been linked to hair loss, but the absolute risk is small and rapid weight loss may be part of the explanation. Here is what the evidence shows.
Read the Full Bite →
Cell & Molecular BiologyGLP-1 links the gut, pancreas, stomach, and brain. Here is how the pathway controls blood sugar, appetite, gastric emptying, and weight.
Read the Full Bite →
Clinical Research & TrialsOral and injectable Wegovy use the same drug but differ in dosing, absorption, and convenience. Here is how the evidence compares for obesity treatment.
Read the Full Bite →
Clinical Research & TrialsSemaglutide and tirzepatide reduce lean mass during weight loss, but mostly reduce fat. Here is what DXA studies show about muscle, sarcopenia, and resistance training.
Read the Full Bite →
Diabetes & MetabolismSemaglutide and tirzepatide withdrawal trials show substantial weight regain after treatment stops. Here is what the evidence says and what it does not.
Read the Full Bite →
Clinical Research & TrialsIn the SURMOUNT-5 head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide at 72 weeks, but the comparison has important limits.
Read the Full Bite →
Diabetes & MetabolismNausea and other gastrointestinal symptoms are common with GLP-1-based medicines, while pancreatitis, gallbladder disease, dehydration, and other serious risks are less frequent.
Read the Full Bite →
Diabetes & MetabolismGIP and GLP-1 both increase meal-stimulated insulin secretion, but their biology differs. Tirzepatide activates both receptors, creating a distinct dual-incretin drug profile.
Read the Full Bite →
Endocrinology & HormonesWhy 'low vitamin D' is common — and why megadoses aren't the fix.
Read the Full Bite →